About Neoleukin Therapeutics
Neoleukin Therapeutics is a Healthcare company based in Seattle (United States) founded in 2003, and was acquired by Aquinox Pharma in August 2019. Therapeutic proteins are developed for immunological disorders using computational methods. Neoleukin Therapeutics has raised $4.72 million across 1 funding round from investors including Aquinox Pharma. Its chief executive, as recorded, is Jonathan Drachman. Its focus areas include Life Sciences, Immunotherapy, Small Molecule and Diversified. Its legal entity is AQUINOX PHARMACEUTICALS, INC. Its competitors include Moderna, BeiGene and Biogen; 3 of its 3 listed competitors have raised funding.
Company details
Neoleukin Therapeutics was founded in 2003 and is headquartered in Seattle, United States. Operations focus on the biotechnology sector, where advanced computational approaches are employed to design de novo therapeutic proteins. These proteins target immunological disorders, including cancer and autoimmunity, by mimicking IL-2 signaling without CD25 binding. Enhanced efficacy, reduced toxicity, greater stability, and improved pharmacokinetics are achieved through precise intermolecular interactions.
- Headquarters Seattle, United States
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website neoleukin.com
- Social LinkedIn X
- Acquired by Aquinox Pharma (Aug 2019)
- Legal Name Aquinox Pharmaceuticals, Inc
- Total Equity Funding$4.72M (USD)
in 1 rounds
- Latest Funding Round$4.72M (USD), Series A
Feb 2011
- Investors
- Acquired byAquinox Pharma
(Aug 2019)
Funding Insights of Neoleukin Therapeutics
Neoleukin Therapeutics has successfully raised a total of $4.72M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.72 million completed in February 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.72M
- Total Rounds 1
- Last Round Series A β $4.72M
- First Round $4.72M
(Feb 2011)
All 1 funding rounds of Neoleukin Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2011 | $4.72M | Series A | β | β | β |
1 investors in total: 1 institutional.
Investors in Neoleukin Therapeutics
Neoleukin Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Aquinox Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Small molecule targeting PI3K pathway. | 2004 | aqxpharma.com | Vancouver, Canada |
Investor details for Neoleukin Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Neoleukin Therapeutics
11 people are tracked at Neoleukin Therapeutics (2 in leadership, 8 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Jonathan Drachman | CEO & President | Leadership |
Priti Patel | Chief Medical Officer | Leadership |
Todd Simpson | Board Member | Board & advisors |
Sarah Noonberg | Board Member | Board & advisors |
Cantey Boyd | Board Member | Board & advisors |
Daniel-Adriano Silva | Scientific Advisor | Board & advisors |
Erin Lavelle | Board Member | Board & advisors |
Martin Babler | Board Member | Board & advisors |
Rohan Palekar | Board Member | Board & advisors |
Kamran Alam | Senior Strategic Advisor | Board & advisors |
James Chesko | Formulation Scientist | Team |
Complete people profiles for Neoleukin Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Neoleukin Therapeutics
4 dated milestones of Neoleukin Therapeutics across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Neoleukin Therapeutics is founded.
- Funding First funding round of $4.7M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Aquinox Pharma.
Competitors of Neoleukin Therapeutics
Neoleukin Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BeiGene and Biogen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. |
Detailed competitors of Neoleukin Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Neoleukin Therapeutics (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neoleukin Therapeutics
Complete news archive for Neoleukin Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neoleukin Therapeutics
Neoleukin Therapeutics was founded in 2003 and raised its 1st funding round 8 years after it was founded.
Neoleukin Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Jonathan Drachman is the CEO of Neoleukin Therapeutics, as recorded in our data.
Neoleukin Therapeutics is a funded company, having raised a total of $4.72M across 1 funding round to date. The company's 1st funding round was a Series A of $4.72M, raised on Feb 2011.
Neoleukin Therapeutics was founded in 2003 and is headquartered in Seattle, United States. Operations focus on the biotechnology sector, where advanced computational approaches are employed to design de novo therapeutic proteins. These proteins target immunological disorders, including cancer and autoimmunity, by mimicking IL-2 signaling without CD25 binding. Enhanced efficacy, reduced toxicity, greater stability, and improved pharmacokinetics are achieved through precise intermolecular interactions.
Neoleukin Therapeutics has 1 investor. Key investors include Aquinox Pharma.
Neoleukin Therapeutics operates through Aquinox Pharmaceuticals, Inc.
Yes. Neoleukin Therapeutics was acquired by Aquinox Pharma in August 2019.

